Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients

BACKGROUND: Clopidogrel is an antiplatelet drug used in the treatment of ischemic stroke. Safety and efficacy of clopidogrel has been confirmed in CAPRIE, PRoFESS trials. However, these studies focused on patients aged less than 75 years. CYP2C19 polymorphisms resulted in individual differences in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Changqing, Jia, Weihua, Li, Jian, Li, Fangfei, Ma, Jing, Zhou, Lichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941922/
https://www.ncbi.nlm.nih.gov/pubmed/33685396
http://dx.doi.org/10.1186/s12883-021-02127-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941922/
https://www.ncbi.nlm.nih.gov/pubmed/33685396
http://dx.doi.org/10.1186/s12883-021-02127-6

Ejemplares similares